BioBeats company

Mental and substance use disorders constitute 10.4% of the global burden of disease and are the leading cause of disability among all disease groups.The global direct and indirect economic costs of mental disorders were estimated at US$2.5 trillion in 2010, and are growing. Both direct and indirect costs of mental disorders are expected to double by 2030. Current clinical and social provision are inadequate and rely on therapeutic devices that cannot track neurological and physiological correlates to psychological progress. Smartphones and wearables brought real-time data. BioBeats is the result of 15 years of research, 5 of which have been in commercial/clinical/consumer deployment. Our team fuses work at the Institute of Biomedical Engineering and the Social Cognition Lab at the University of Oxford to use real-time data not only to bring physiological data to psychological therapy but to produce machine learning that can predict onset of disorder and intervene early.
Technology: NeuroTech
Industry: Artificial Intelligence, Data and Analytics, Health Care, Science and Engineering, Software, Sports
Headquarters: London, England, United Kingdom
Founded Date: 2012-01-01
Employees Number: 11-50
Funding Status: M&A
Investors Number: 18
Total Funding: $6.6M
Estimated Revenue: $1M to $10M
Last Funding Type: Venture - Series Unknown

Visit Website
privacy@biobeats.com
https://twitter.com/joinbiobeats
Register and Claim Ownership